2026³â 05¿ù 06ÀÏ ¼ö¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Parse Biosciences Announces Evercode TCR and Gene Capture

New immune profiling and enrichment capabilities expand applications and facilitate scalability
´º½ºÀÏÀÚ: 2023-02-08

HOLLYWOOD, FLA.-- February 08, 2023 -- Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ TCR and Gene Capture. These new solutions expand the Parse Biosciences portfolio to address higher scale and immune profiling applications.

Evercode TCR provides researchers the ability to profile T cell receptors (TCR) together with whole transcriptomes in single cells at scale. The diversity of possible TCRs in the immune repertoire is enormous, yet the low throughput of existing tools have limited the ability to capture this complexity at high resolution. Evercode TCR will enable researchers to measure whole transcriptomes and paired TCR sequences - both alpha and beta chains - in up to 1 million cells. Combining TCR sequences with gene expression at this scale makes it possible to track TCR clonotypes across different T cell subtypes and activation states to understand the immune repertoire at exceptional resolution.

Parse also announced the launch of Gene Capture, a solution to reduce sequencing needs for larger studies. Gene Capture focuses sequencing on the most relevant genes, making it possible to efficiently scale projects to millions of cells and hundreds of samples. The solution allows researchers to enrich for 100s-1000s of genes, requiring 10 times less sequencing. Researchers can order a predesigned panel of approximately 1,000 genes relevant to immunology, the Immune1000, or design a panel unique to their needs.

“Increasingly, we see the need to support larger single cell RNA sequencing studies. Biology is complex and requires robust studies across multiple samples, timepoints, and many individual cells to fully capture this complexity,” notes Parse co-founder and CEO Alex Rosenberg, Ph.D. “Parse’s technology has already brought unprecedented scale to the market, and these new tools will expand these capabilities, unlocking new applications in both the research and translational space.”

Charles Roco, Ph.D., Parse co-founder and CTO, will present on the capabilities of Parse’s Evercode TCR and Gene Capture products at the AGBT General Meeting this week at his session, “Broadening Access to Scalable Single Cell Sequencing,” on Wednesday, February 8 at 3:35 pm in the Grand Ballroom.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Quectel Introduces FGH200M Wi-Fi HaLow Module for massive IoT Deployments
AMOLED Smartphone Display Shipments Expected to Decline Sharply in 2026
Axelspace-Led Consortium Chosen for Japan Space Fund Project on Next-Gen Earth Observation Satellite Technology
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering
Boomi Builds Analyst Momentum Across Integration, API Management, Data Management, and Agentic AI
Quectel Expands Mid-tier 5G Portfolio with New RedCap 3GPP Release 17 Variants

 

Takeda¡¯s Zasocitinib Shows Rapid, Durable Skin Clearance in Once-Dail...
Regnology Announces Next-Generation Ascend Platform with Agentic AI, A...
SS&C Unveils WorkHQ to Power Enterprise Agentic Automation
AI Ambitions at Risk as Only 14% of Enterprises Fully Realize Cloud Va...
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2...
Global PC Shipments Grew 3% in 1Q26 as Supply Chain Impacts Emerged
NBA Bounce Brings Action-Packed Basketball Fun to LG Electronics¡¯ Sma...

 


°øÁö»çÇ×
'º£³×ÀÍ' Áß¹® Ç¥±â 宝Ò¬ìÌ, 'À̺ñÁî: ÀÌÁö' Áß¹® Ç¥±â æ¶币òª...
¿¡³ÊÀ¯ Enereu 额Òö äþÒö
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´º½ºÁö Áß¹®Ç¥±â´Â À½Â÷ Ç¥±â¹æ½Ä '纽ÞÙó¢ ´Ï¿ì½ºÁö'
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®À¯ºñ Alliuv ä¹备: ä¹êó备, ¾Ë¶ã Althle ä¹÷åìÌ
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØ ä¹ì³ÜØ
´º½º±×·ì Á¤º¸ ¹Ìµð¾î ºÎ¹® »óÇ¥µî·Ï
¾ËÇÁ·Ò °è¿­ »óÇ¥, »óÇ¥µî·Ï ¿Ï·á

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..